ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1724

More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database

Anna Molto1, Barbara Roux2, Diep Tran2, Aya Ajrouche2, nathalie costedoat-Chalumeau3, Elisabeth Elefant4, Vassilis Tsatsaris5, Jeanne Fresson6, Brigitte Bader-Meunier7, Bruno Fautrel8 and Florence Tubach2, 1Rheumatology department, Cochin hospital, APHP, Paris, France, 2CEPHEPI, APHP, Paris, France, 3Inserm DR Paris 5, Paris, France, 4Teratogenic agents refernce center (CRAT) , Hôpital Trousseau, APHP, Paris, France, 5Obstetrics Department, Port Royal Maternity, Cochin Hospital, APHP, Paris, France, 6CHU Nancy, Nancy, France, 7Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, 8Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France

Meeting: ACR Convergence 2021

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), pregnancy, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Women with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondyloarthritis (SpA)) have been reported to have poorer pregnancy outcomes than the general population. The objective of this analysis was to describe the singleton pregnancy outcomes of women with CRID in France over the past decade.

Methods: This is a retrospective cohort study within the French Healthcare database (SNDS), which covers 97% of the French population. Adult women were included if they had RA or SpA according to CIM-10 codes, had started a singleton pregnancy between 2008 and 2017 (index date), and were continuously covered by this health insurance from 1‐year before pregnancy onset to 1-year after end of the pregnancy or death (whichever came first). Both maternal and pregnancy outcomes were considered. Outcomes were identified either by ICM-10 codes or hospital discharge summaries between 2008 and 2018.

Results: Among the 35,737 adult women with a CRID (40.7% with RA and 59.3% with SpA) and a past history of DMARD reimbursement, 11,274 (41.7%) started a singleton pregnancy during the study period. Among them, 6,501 (57.7%) were exposed to at least one DMARD preconceptionally (6 months before last menstrual period) and during pregnancy.

Mean (SD) age of women at the start of pregnancy was 32 (5) years, and disease duration was 4 (4) years. Live-birth represented by far the most frequent pregnancy outcome (76.9%), but 56.6% patients presented at least one unfavorable outcome among those listed in the table.

Conclusion: More than 75% pregnancies in patients with CRID resulted in a live-birth, but half of patients presented at least an unfavorable pregnancy outcome. Prevalence of miscarriage was lower than reported in the literature, probably reflecting the fact that very early miscarriages often do not need hospitalization/ specific intervention, and thus are difficult to identify in claims databases. Maternal and infant outcomes seemed comparable to general population. Whether medications had an impact on such outcomes needs further evaluation.

Unfavourable pregnancy outcomes in patients with chronic rheumatic inflammatory diseases


Disclosures: A. Molto, None; B. Roux, None; D. Tran, None; A. Ajrouche, None; n. costedoat-Chalumeau, None; E. Elefant, None; V. Tsatsaris, None; J. Fresson, None; B. Bader-Meunier, None; B. Fautrel, AbbVie, 5, Pfizer, 5, Janssen, 2, Medac, 2, Novartis, 2, Sanofi-Genzyme, 2, Roche, 2, UCB, 2, Abbvie, 2, Amgen, 2, Biogen, 2, BMS, 2, Celltrion, 2, Fresenius Kabi, 2, Galapagos, 2, Gilead, 2, Lilly, 2, 5, MSD, 2, MSD, 5, Mylan, 2, Nordic Pharma, 2, Pfizer, 2, Sandoz, 2, SOBI, 2; F. Tubach, None.

To cite this abstract in AMA style:

Molto A, Roux B, Tran D, Ajrouche A, costedoat-Chalumeau n, Elefant E, Tsatsaris V, Fresson J, Bader-Meunier B, Fautrel B, Tubach F. More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/more-than-50-of-women-with-chronic-rheumatic-inflammatory-diseases-present-an-unfavorable-pregnancy-outcome-a-descriptive-analysis-of-the-national-french-healthcare-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/more-than-50-of-women-with-chronic-rheumatic-inflammatory-diseases-present-an-unfavorable-pregnancy-outcome-a-descriptive-analysis-of-the-national-french-healthcare-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology